The present study is the first demonstration using tumor-associated antigen (TAA)-derived CTL and helper peptides in an in vivo mouse model that combination vaccine with TAA-derived CTL and helper peptides induced the higher infiltration of the TAA-specific CD8+ CTLs than vaccination with the CTL peptide alone in tumor sites. The gene discussed is CD8A; the disease is neoplasm.